Choosing the right CRO as a partner for your drug development programs is a vitally important step to achieving critical decision making early on for important milestones, and ultimately getting your molecule from discovery to market efficiently.

Altasciences has completed a Phase I study for the development of gimsilumab, a fully human monoclonal antibody that targets granulocyte-macrophage colony stimulating factor (GM-CSF), found to be up-regulated in SARS CoV-2 in patients with or at risk of developing acute respiratory distress syndrome (ARDS).